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OBJECTIVES We evaluated left atrial appendage obliteration in high-risk patients with atrial fibrillation
(AF).
BACKGROUND Left atrial appendage thrombosis and embolization is the principal mechanism of stroke in
AF. Anticoagulation is underutilized and often contraindicated.
METHODS Thoracoscopic Left Appendage, Total Obliteration, No cardiac Invasion (LAPTONI) was
undertaken with a loop snare in eight patients and a stapler in seven patients, median age 71
years, with clinical risk factors for stroke and with an absolute contraindication to or failure
of prior thrombosis prevention with warfarin. Eleven patients had a history of prior
thromboembolism. One patient took sustained warfarin during follow-up.
RESULTS The LAPTONI procedure was completed in 14 of 15 patients, and 1 patient required urgent
conversion to open thoracotomy because of bleeding. Patients have been followed up for 8 to
60 months, mean 42  14 months. One fatal stroke occurred 55 months after surgery, and
one non-disabling stroke three months after surgery. Two other deaths occurred, one after
coronary bypass surgery and the other from hepatic failure. The subgroup of 11 patients with
prior thromboembolism had an annualized rate of stroke of 5.2% per year (95% confidence
interval [CI] 1.3 to 21) after LAPTONI, which compares to a rate of 13% per year (95% CI
9.0 to 19) for similar aspirin-treated patients from the Stroke Prevention in Atrial Fibrillation
trials (p  0.15).
CONCLUSIONS The LAPTONI procedure appears technically feasible without immediate disabling neuro-
logic morbidity or mortality, and it demonstrates low post-operative event rates and a
statistical trend toward thromboembolic risk reduction in high-risk AF patients. (J Am Coll
Cardiol 2003;42:1249–52) © 2003 by the American College of Cardiology Foundation
The stroke rate in patients with atrial fibrillation (AF) older
than 75 years of age is 8.1% per year with one clinical risk factor
and is 12% per year at any age in clinical trial populations with
a history of prior thromboembolism (1,2). Three-year stroke
rates in elderly nursing home patients not anticoagulated are in
excess of 50% (3). Fear of hemorrhagic complications prevents
utilization of anticoagulation in these high-risk patients.
See page 1259
Most thrombi in non-rheumatic AF originate in the left
atrial (LA) appendage (4), suggesting the origin of throm-
boembolism (5). Left atrial appendage obliteration is com-
monly performed in a variety of cardiac surgical operations,
but its feasibility and value as a stand-alone stroke preven-
tative strategy is undefined. A catheter-based LA appendage
occluder device has recently been developed and tested in
animals, and a first group of humans has undergone device
implantation (6). However, there are no data to support the
hypothesis that appendage obliteration reduces stroke. We
present data on isolated surgical obliteration of the LA
appendage in 15 patients with a mean follow-up in excess of
three years. Data on seven of these patients were previously
published shortly after surgery (7).
METHODS
Patient population. Patients at two medical centers with
chronic or intermittent AF were identified from routine
clinical practice with at least one risk factor for stroke (prior
thromboembolism, hypertension, age 75 years, left ven-
tricular dysfunction, or diabetes mellitus) and either an
absolute contraindication to warfarin or documentation of
prior LA appendage thrombosis despite adequate oral an-
ticoagulation. The protocol was approved by the institu-
tional review boards of both institutions.
Thoracoscopic closure of the LA appendage. Informed
consent was obtained before surgery. Each patient was
anesthetized and intubated with a double lumen endotra-
cheal tube. Transesophageal echocardiography (TEE) con-
From the *Mayo Clinic Jacksonville, Jacksonville, Florida; †W. Dudley Johnson
Heart Care Center, Milwaukee, Wisconsin; ‡Biostatistical Consultant, Minot, North
Dakota; §Mayo Clinic, Rochester, Minnesota. Supported by grants from Ethicon
Endosurgery and the Mayo Foundation for Medical Research.
Manuscript received December 5, 2002; revised manuscript received January 30,
2003, accepted February 20, 2003.
Journal of the American College of Cardiology Vol. 42, No. 7, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00953-7
firmed the absence of LA appendage thrombus at the time
of surgery. Patients were positioned, prepared, and draped
as for a left or left-lateral thorocotomy. Three to five
thoracoscopic incisions were made to introduce the video-
assisted thoracoscopic instruments. Using a double-lumen
endotracheal tube, the volume of the left lung was reduced.
Up to 4 cm pressure CO2 insufflation in the left pleural
space was used specifically to reduce or eliminate the
potential for air embolus in the event of an inadvertent tear.
The pericardium was opened with scissors at a site parallel
to the phrenic nerve. The atrial appendage tip was grasped
using a non-traumatic clamp, and an endoloop snare was
fixed as a tie to the appendiceal tip. A second endoloop was
introduced over the first tie and manipulated with the
assistance of instruments to the appendiceal base, where it
was cinched to occlude the appendage. Alternatively, a row
of staples was placed. Occlusion was documented by TEE
as the abrupt appearance of dense, stationary, high-contrast
echoes (Fig. 1). At the conclusion of the procedure, the
pericardium was left open, the CO2 was evacuated, and tube
thoracoscopy suction was employed.
Follow-up. Patients were regularly contacted after the
procedure and questioned regarding neurologic symptoms.
Contact was by telephone interview at six-month intervals.
Medical records from hospitalizations were reviewed. The
protocols did not include late imaging for verification of
persistent occlusion of the LA appendage.
Statistical methods. Patient exposure for stroke was com-
puted as the number of days from LAPTONI to date of first
stroke, with exposure censored on the date of death or last
day of follow-up if no stroke occurred. Similarly, patient
exposure for death was computed as the number of days
from LAPTONI to the date of death, with censorship on
the last day of follow-up. Overall event rates were calculated
by dividing the number of events by the total patient
observation, with 95% confidence intervals calculated using
a Poisson distribution. Survival curves were computed using
the Kaplan-Meier method and compared to reference pop-
ulations. All statistical tests were two-sided, and statistical
significance was accepted at the 0.05 level.
RESULTS
Patients’ characteristics are listed in Table 1. Ages varied
from 24 to 81 years, mean  SD 67  15 years, median 71
years. Eleven patients had a history of prior thromboembo-
lism, 12 had a history of hypertension, and 11 had bleeding
diatheses including five with prior intracranial hemorrhage
and one with prior meningioma surgery. Hospital length of
stay varied with from two to 20 days. Post-operative
complications included bleeding from a torn accessory atrial
appendage, necessitating urgent thoracotomy in one patient.
One patient with hypertrophic nonobstructive cardiomyop-
athy experienced refractory pump failure and a prolonged
intensive care unit stay after the procedure. One patient had
atelactasis, one had prolonged air leak, one underwent
investigation and treatment of genitourinary bleeding, and
one had chronic pleuritic pain. There were no peri-operative
neurologic events.
Median follow-up duration was 42 months. During this
time, two strokes—one non-disabling and one fatal—
Abbreviations and Acronyms
AF  atrial fibrillation
AFI  Atrial Fibrillation Investigators
EAFT  European Atrial Fibrillation Trial
LA  left atrial
LAPTONI  Left Appendage Total Obliteration,
No cardiac Invasion
SPAF  Stroke Prevention in Atrial Fibrillation
TEE  transesophageal echocardiography
Figure 1. Intraoperative transesophageal echocardiographic images of the left atrial appendage before (left) and after (right) LAPTONI.
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occurred. One patient with a history of multiple prior
strokes had a small stroke during hospitalization for pneu-
monia. He made a complete recovery and remains well 40
months after surgery. One patient, age 79 at surgery, with
prior stroke, congestive heart failure, severe left ventricular
dysfunction, and multiple subdural hematomas, suffered a
fatal stroke and intracranial hemorrhage 55 months after
surgery. One patient died after coronary bypass surgery,
performed 34 months after LAPTONI. One patient with
chronic hepatitis C, variceal and small intestinal blood loss,
and prior systemic embolism died from hepatic failure.
Overall rate of stroke was 4.0% per patient-year, 95%
confidence interval (CI) 1.0 to 16. Rate of fatal stroke was
2.0% per patient-year, 95% CI 0.3 to 13. Rate of death or
stroke was 6.0% per patient-year, 95% CI 2.0 to 19. Among
the 11 patients with a history of prior thromboembolism,
stroke rate was 5.2% per year, 95% CI 1.3 to 21, which
compares to 13% per year, 95% CI 9.0 to 19 in aspirin-treated
patients with prior thromboembolism in the Stroke Prevention
in Atrial Fibrillation (SPAF) studies (p 0.15, not significant)
(8). In four patients without a history of prior stroke, the stroke
rate was 0% per year after LAPTONI, compared to a rate of
2.6% per year, 95% CI 1.9 to 3.6% per year rate of stroke in
SPAF (not statistically significant). Figure 2 presents cumula-
tive freedom from thromboembolism with comparison to rates
in prior studies of similar patients (1,2).
DISCUSSION
The recent publication of a catheter-based LA appendage
occluder device and its use in 30 patients (6) and the absence
of data supporting the safety and efficacy of such a procedure
provided us the impetus to present our results. Our two-
center experience utilized surgical appendage obliteration
with either a loop snare or a stapler, with placement of the
occlusion device at the appendiceal base. Pre-clinical expe-
rience with both techniques documented a smooth LA
architecture with complete obliteration (9). The site of
closure is similar to that documented with the transvascular
occluder (6)—but without the foreign body in immediate
contact with the circulation. Although underpowered for
statistical significance, the observed event rate in our series
of patients with a history of prior thormboembolism is
consistent with the benefits proposed for appendage oblit-
eration. This observation would appear to support the
further development and testing of strategies to reduce
stroke risk in this highest risk segment of the AF population
Table 1. Patient Characteristics and Outcomes
Age/Gender Prior TE Htn ICH
GI/GU
Bleed/Ulcer LOS
Months Free of
Thomboembolism
Months Free of
Death or Disabling
Thomboembolism
81/M* yes no no yes 10 d 46 46
79/F yes no yes no 5 d 60 60
63/M yes yes yes no 3 d 60 60
79/M yes yes no no 3 d 58 58
56/F yes no no yes 10 d 54 54
79/M† yes yes yes yes 2 d 55 55
70/F no yes yes no 6 d 29 29
76/M yes yes yes no 3 d 8 8
63/M yes yes no no 7 d 41 41
78/M‡ yes yes no§ no 20 d 3 40
71/M no yes no yes 3 d 38 38
50/M yes yes no no 4 d 38 38
24/F yes yes no no 5 d 37 37
74/M no yes no yes 12 d 34 34
69/M no yes no yes 7 d 34 34
*Died of hepatic failure, †Fatal stroke 55 months after surgery, ‡Nondisabling stroke 3 months after surgery with full recovery, alive and well 40 months after surgery, §Prior
surgery for meningioma, Died after coronary bypass surgery done 34 months after first surgery.
Htn  hypertension; ICH  intracranial hemorrhage; GI/GU  gastrointestinal/genitourinary; LOS  length of stay; TE  thromboembolism.
Figure 2. Cumulative proportion of 15 patients with atrial fibrillation (AF)
after surgical left atrial appendage obliteration (LAPTONI) without
thromboembolism (straight line). The reference lines are based on
thromboembolism rates for non-anticoagulated AF patients aged 65 to 75
years in the Atrial Fibrillation Investigators’ (AFI) meta-analysis with at
least one risk factor (upper dashed line) (1) and for non-anticoagulated AF
patients of any age with a history of prior thromboembolism in AFI and
the European Atrial Fibrillation Trial (EAFT) (bottom dashed line) (1,2).
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(1,2) in whom the preferred therapy, anticoagulation, is
contraindicated or has previously been insufficient to pre-
vent embolism. Clearly the magnitude of risk varies but may
be very high. In a study of secondary stroke prevention in
AF, non-anticoagulated patients had a 17% per year rate of
stroke or death (2). Age, itself a significant AF stroke risk
factor, was lower in the anticoagulation clinical trials than
the AF population median of 75 years, suggesting that
clinical trial data underestimate the true risk for this group.
Consistent with this, Aronow et al. (3) described 312
persons with AF with an average age of 84 years who
resided in a chronic care facility. Rates of stroke over three
years in those not anticoagulated were 56% in those with no
prior history of thromboembolism and 81% in those with
prior history of thromboembolism (3).
Definitive proof that appendage obliteration by any
technique reduces the risk of thromboembolism can be
obtained only through a randomized clinical trial. However,
data from Cox et al. (10) support the hypothesis that
appendage ligation, a part of the maze procedure, may be
effective in preventing stroke. More than 40% of patients
who undergo the maze operation have transient post-
operative AF, yet only those with mitral valve replacement,
mechanical aortic valve replacement, or Benthall procedure
are routinely anticoagulated. Despite this high rate of
post-operative AF, the rate of post-operative stroke in the
maze procedure population was 0.7% (10). Rates of peri-
operative stroke for coronary bypass associated AF without
maze vary from 2% to 7% (11), and post-operative AF was
a highly significant independent predictor of stroke in the
study of Stamou et al. (12). In addition, despite some
reduction in atrial function in a portion of the post-maze
population, during follow-up of between three months and
11.5 years, the stroke rate has been 0.4% (10). Patients
undergoing maze surgery were relatively young and probably
had a lower intrinsic risk of thromboembolism.
Study limitations. The obvious limitation of this study is
the small numbers of study patients, yielding very wide CIs
for event rates and preventing a definitive statement regard-
ing efficacy. While they suggest a trend toward benefit, the
event rates after LAPTONI fall within the confidence limits
reported in clinical trials with aspirin or no therapy. Second,
the absence of a simultaneous randomized control group
prevents a truly accurate assessment of risk reduction.
Despite the absence of mortality or neurologic morbidity
from LAPTONI in the short term, we did experience
significant, although not unexpected, non-stroke morbidity
in our small series, suggesting that refinements in the
procedure or more careful patient selection may be required.
Cardiac failure in our patient with hypertrophic cardiomy-
opathy, and the prior report from Cox et al. that two of 10
peri-operative deaths in patients undergoing the maze
procedure occurred in patients with hypertrophic cardiomy-
opathy (10), suggest that these patients should be excluded
from the initial application of this procedure.
Conclusions. Surgery to prevent stroke is widely accepted,
as in the case of carotid endarterectomy. Our initial human
experience with LAPTONI in AF documents that it is
technically feasible to perform this procedure without car-
diac invasion, in a relatively elderly population at substantial
risk for AF-related stroke, without producing any disabling
neurologic morbidity in the short term. Our study differs
from the endovascular approach thus far described (6), in
that our patients had higher estimated risk, that no cardiac
invasion or intracardiac foreign body was placed, and that
no immediate post-procedure antithrombotic therapy was
utilized. A statistical trend toward benefit in our patients
with prior thromboembolism was demonstrated with an
average follow-up of 42 months. These data provide support
for the further development of this or other techniques for
appendage obliteration, in hopes of providing an effective
prophylaxis for patients with the highest risk and absolute
contraindications to, or proven inefficacy of, anticoagulation.
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